SDC2 (Syndecan 2)

mIHC analysis indicated reduced Th1 but increased Th2 and Th17 biomarkers in MSI-H CRC. This study identified key genes and immune microenvironment alterations regulated by hsa-miR-99a in CRC, offering novel insights and potential therapeutic targets for CRC treatment.

Applied to plasma samples from patients with various tumors (including colorectal, lung, breast, cervical, liver, and gastric cancers), the technology significantly improved the detection rates up to 100% of tumor-specific methylation biomarkers, such as SDC2, SHOX2, RASSF1A, ZNF671, Septin9, and BMP3. Therefore, this study provides an efficient, universal and user-friendly enrichment and accurate detection of mDNA, laying a methodological foundation for early cancer screening and prognosis assessment.

This study defines a novel molecular subtype for COAD, linking PCD dysregulation to distinct TME remodeling and therapeutic outcomes. Targeting the MDK-SDC2 axis with agents such as sunitinib may offer a promising strategy to overcome stromal-mediated immunotherapy resistance in the most lethal PCDS3 tumors.

We also discuss the repurposing of the oral adsorbent AST-120 and emerging bacteriophage therapies as strategies to disrupt this oncogenic axis. This review offers a comprehensive framework for stratified management of CKD-associated CRC.

The findings reveal a complex and heterogeneous relationship between Syndecan-2 methylation and its protein expression during colorectal cancer progression, suggesting stage-specific regulatory mechanisms. Further multiomics studies are warranted to elucidate the underlying functional dynamics.

The combined methylation assay of SDC2, SFRP2, and TFPI2 outperformed FOBT and CEA in detecting CRC and AA, although further optimization is required for AA detection. Its high specificity and compatibility with routine screening procedures underscore its potential as a tool for detecting colorectal neoplasia.

Deeks' funnel plot asymmetry tests indicated no statistically significant publication bias (p = 0.48 and 0.54). In conclusion, fecal mSDC2 testing demonstrates high diagnostic accuracy for CRC detection when compared to individuals with normal mucosa and moderate performance against benign colorectal lesions. These findings suggest that mSDC2 may serve as a promising noninvasive biomarker to complement existing CRC screening methodologies.

Among those with a positive meSDC2 test, a family history of CRC was a significant predictor of any CRN (p=0.029) and advanced neoplasia (p=0.003). A stool DNA-based meSDC2 test in average-risk individuals for CRC revealed a high PPV for any CRN in a real-world setting, highlighting its potential as a screening modality in programmatic CRC screening.

DNA methylation and microRNA biomarkers hold strong promises for non-invasive CRC screening. Multi-marker panels demonstrate superior diagnostic accuracy and may provide a cost-effective, scalable approach for early CRC detection in resource-limited settings.

This study revealed the effectiveness of the mSDC2 test and FIT in detecting advanced colorectal neoplasia in a large Chinese population in a real-world setting, and indicated a possible improvement in adherence to colonoscopy for the mSDC2 test. Further studies with improved comparability and longer follow-up are warranted to clarify its clinical utility.

Image analysis confirmed that callus morphology and growth were preserved, compared with the control. These results highlight the safe use of FHSPF2 and FHSPG1 NPs in agricultural biotechnology and biomedical applications, providing a sustainable approach to mitigate heavy metal stress and enhance plant resilience.

The stool meSDC2 test demonstrated a high positivity rate in CRC but showed low positivity rates in other cancers, except in biliary tract cancer. This indicates that the stool meSDC2 test has a high specificity for CRC, as the results are minimally influenced by other cancer types.